← All organizations
Highest phase reached
Phase 3
First clinical trial
Jan 1, 2005Last known activity
Jun 1, 2014
Acquired by Catalyst Biosciences on Jan 1, 2015
Timeline
1950s
- Mar 1, 1956
mecamylamine— NDA Secondary Org
1990s
- Jan 1, 1997
Targacept— Founded
2010s
- Jan 1, 2015
Catalyst Biosciences— Acquired By
Drugs by trial phase (9 distinct, 22 trials)
Phase 3 (1 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Phase 1 (1 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Asthma
- Attention Deficit Disorder with Hyperactivity
- Cognitive Dysfunction
- Constipation
- Dementia
- Depression
- Depressive Disorder
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Disease
- Gastroparesis
- Hyperkinesis
- Hypertension
- Irritable Bowel Syndrome
- Major Depressive Disorder
- Memory Disorders
- Schizophrenia
- Syndrome
- Urinary Bladder, Overactive
Marketed drugs (1)
Recent trials (24)
- NCT02187094Lead sponsorPhase 1/Phase 2Jun 1, 2014
- NCT01868516Lead sponsorPhase 2May 1, 2013
- NCT01488929Lead sponsorPhase 2Dec 1, 2011
- NCT01472991Lead sponsorPhase 2Nov 1, 2011
- NCT01466088Lead sponsorPhase 2Oct 1, 2011
- NCT01296087Lead sponsorPhase 2Feb 1, 2011
- NCT01293669Lead sponsorPhase 2Jan 1, 2011
- NCT01254448Lead sponsorPhase 1Sep 1, 2010
- NCT01197508CollaboratorPhase 3Sep 1, 2010
- NCT01180400CollaboratorPhase 3Sep 1, 2010
- NCT01153347CollaboratorPhase 3Jun 1, 2010
- NCT01152554CollaboratorPhase 3Jun 1, 2010
- NCT01157078CollaboratorPhase 3Jun 1, 2010
- NCT01124708Lead sponsorPhase 2May 1, 2010
- NCT01149200Lead sponsorPhase 2May 1, 2010
Details
- Founded
- Winston Salem, NC, US Jan 1, 1997
- Last known activity
- Jun 1, 2014